Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors

This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Neuro-Oncology, Pediatrics
Phase III
Children
Therapy (NOS)
Memantine, Placebo
Esbenshade, Adam
International
Vanderbilt University
09-13-2022
Treatment
COGACCL2031
NCT04939597

Eligibility

4 Years
BOTH
NO

To learn more about any of our clinical
trials, call 615-936-8422.